相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cannabinoid Modulation of Dopamine Release During Motivation, Periodic Reinforcement, Exploratory Behavior, Habit Formation, and Attention
Erik B. Oleson et al.
FRONTIERS IN SYNAPTIC NEUROSCIENCE (2021)
Activation of 5-HT1A and 5-HT7 receptors enhanced a positively reinforced long-term memory
Rocio Solis-Guillen et al.
BEHAVIOURAL BRAIN RESEARCH (2021)
The Effects of Cannabidiol Oil on Noninvasive Measures of Muscle Damage in Men
Kristen C. Cochrane-Snyman et al.
MEDICINE & SCIENCE IN SPORTS & EXERCISE (2021)
Alzheimer's disease
Philip Scheltens et al.
LANCET (2021)
Anxiety disorders
Brenda W. J. H. Penninx et al.
LANCET (2021)
Cannabidiol prevents several of the behavioral alterations related to cocaine addiction in mice
Juan Carlos Ledesma et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2021)
The CANBACK trial: a randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain
Bronwyn Bebee et al.
MEDICAL JOURNAL OF AUSTRALIA (2021)
Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone in a human laboratory pain model
Kelly E. Dunn et al.
NEUROPSYCHOPHARMACOLOGY (2021)
The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial
Marcel O. Bonn-Miller et al.
PLOS ONE (2021)
Topical Cannabinoids for Treating Chemotherapy-Induced Neuropathy: A Case Series
Stacy D'Andre et al.
INTEGRATIVE CANCER THERAPIES (2021)
Agitation, Oxidative Stress, and Cytokines in Alzheimer Disease: Biomarker Analyses From a Clinical Trial With Nabilone for Agitation
Myuri Ruthirakuhan et al.
JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY (2020)
The genetic architecture of Parkinson's disease
Cornelis Blauwendraat et al.
LANCET NEUROLOGY (2020)
Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-HT1A and TRPV1 receptor mechanisms
Ewa Galaj et al.
NEUROPHARMACOLOGY (2020)
Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study
Alex Capano et al.
POSTGRADUATE MEDICINE (2020)
Transient and sustained effects of dopamine and serotonin signaling in motivation-related behavior
Sho Yagishita
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2020)
Dopamine and Addiction
Roy A. Wise et al.
ANNUAL REVIEW OF PSYCHOLOGY, VOL 71 (2020)
The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities
Dixon H. Xu et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2020)
Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease
Stephanie Martins de Faria et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2020)
Dopaminergic neuroprotective effects of rotigotine via 5-HT1A receptors: Possibly involvement of metallothionein expression in astrocytes
Nami Isooka et al.
NEUROCHEMISTRY INTERNATIONAL (2020)
Orally consumed cannabinoids provide long-lasting relief of allodynia in a mouse model of chronic neuropathic pain
Antony D. Abraham et al.
NEUROPSYCHOPHARMACOLOGY (2020)
Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: A human laboratory study
Reilly R. Kayser et al.
DEPRESSION AND ANXIETY (2020)
Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone
Marina Peball et al.
ANNALS OF NEUROLOGY (2020)
Amyotrophic lateral sclerosis: a clinical review
P. Masrori et al.
EUROPEAN JOURNAL OF NEUROLOGY (2020)
Cannabinoids for Pain Control During Medical Abortion A Randomized Controlled Trial
Alyssa Covelli Colwill et al.
OBSTETRICS AND GYNECOLOGY (2020)
Evaluation of the preclinical analgesic efficacy of naturally derived, orally administered oil forms of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and their 1:1 combination
Katja Linher-Melville et al.
PLOS ONE (2020)
Mirtazapine exerts astrocyte-mediated dopaminergic neuroprotection
Ryo Kikuoka et al.
SCIENTIFIC REPORTS (2020)
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Amir Garakani et al.
FRONTIERS IN PSYCHIATRY (2020)
Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders
Maria S. Garcia-Gutierrez et al.
BIOMOLECULES (2020)
Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders
Sudhir M. Baswan et al.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY (2020)
Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study
Maureen A. Leehey et al.
CANNABIS AND CANNABINOID RESEARCH (2020)
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition
Clare Walton et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Epilepsy-Definition, Classification, Pathophysiology, and Epidemiology
Jessica Falco-Walter
SEMINARS IN NEUROLOGY (2020)
Cannabinoid Augmentation of Exposure-Based Psychotherapy for Obsessive-Compulsive Disorder
Reilly R. Kayser et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2020)
Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial
Jolana Markova et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2019)
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain
Danilo De Gregorio et al.
PAIN (2019)
Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results
Linda C. Laux et al.
EPILEPSY RESEARCH (2019)
Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
Nilo Riva et al.
LANCET NEUROLOGY (2019)
Medical Cannabis: Effects on Opioid and Benzodiazepine Requirements for Pain Control
Megan O'Connell et al.
ANNALS OF PHARMACOTHERAPY (2019)
Global, regional, and national burden of epilepsy, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Ettore Beghi et al.
LANCET NEUROLOGY (2019)
Epidemiology of amyotrophic lateral sclerosis: an update of recent literature
Elisa Longinetti et al.
CURRENT OPINION IN NEUROLOGY (2019)
Quality of life in adults enrolled in an open-label study of cannabidiol (CBD) for treatment-resistant epilepsy
Tyler E. Gaston et al.
EPILEPSY & BEHAVIOR (2019)
Cannabidiol Treatment Might Promote Resilience to Cocaine and Methamphetamine Use Disorders: A Review of Possible Mechanisms
Claudia Calpe-Lopez et al.
MOLECULES (2019)
Cannabinoid modulation of opioid analgesia and subjective drug effects in healthy humans
Shanna Babalonis et al.
PSYCHOPHARMACOLOGY (2019)
Nabiximols for the Treatment of Cannabis Dependence A Randomized Clinical Trial
Nicholas Lintzeris et al.
JAMA INTERNAL MEDICINE (2019)
A Novel Self-Emulsifying Drug Delivery System (SEDDS) Based on VESIsorb® Formulation Technology Improving the Oral Bioavailability of Cannabidiol in Healthy Subjects
Katharina Knaub et al.
MOLECULES (2019)
Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial
Orrin Devinsky et al.
EPILEPSIA (2019)
Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series
Lucas Elms et al.
JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE (2019)
Increased Serotonin Transporter Expression in Huntington's Disease Patients Is Not Consistently Replicated in Murine Models
Yanqing He et al.
JOURNAL OF HUNTINGTONS DISEASE (2019)
Novel therapeutic targets for amyotrophic lateral sclerosis
Gitika Batra et al.
INDIAN JOURNAL OF PHARMACOLOGY (2019)
Huntington's disease: a clinical review
P. McColgan et al.
EUROPEAN JOURNAL OF NEUROLOGY (2018)
The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain
Giulia Donvito et al.
NEUROPSYCHOPHARMACOLOGY (2018)
Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder
Matthew N. Hill et al.
NEUROPSYCHOPHARMACOLOGY (2018)
Effects of Cannabidiol on Morphine Conditioned Place Preference in Mice
James Roland Markos et al.
PLANTA MEDICA (2018)
Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases
Michael G. Erkkinen et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2018)
The pharmacokinetics and the pharmacodynamics of cannabinoids
Catherine J. Lucas et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain
Aron H. Lichtman et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2018)
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome
Orrin Devinsky et al.
NEUROLOGY (2018)
Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability
Ziva D. Cooper et al.
NEUROPSYCHOPHARMACOLOGY (2018)
Cannabinoid CB1 and CB2 Receptors, and Monoacylglycerol Lipase Gene Expression Alterations in the Basal Ganglia of Patients with Parkinson's Disease
Francisco Navarrete et al.
NEUROTHERAPEUTICS (2018)
Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial
Jose M. Trigo et al.
PLOS ONE (2018)
Cannabidiol Regulates Long Term Potentiation Following Status Epilepticus: Mediation by Calcium Stores and Serotonin
Nicola Maggio et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2018)
Role of the endocannabinoid system in drug addiction
Jorge Manzanares et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Cannabinoid Delivery Systems for Pain and Inflammation Treatment
Natascia Bruni et al.
MOLECULES (2018)
Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease
Andrew J. Aschenbrenner et al.
NEUROLOGY (2018)
The Emerging Evidence of the Parkinson Pandemic
E. Ray Dorsey et al.
JOURNAL OF PARKINSONS DISEASE (2018)
Pooled analysis of three randomized, double-blind, placebo controlled trials with rimonabant for smoking cessation
Jason D. Robinson et al.
ADDICTION BIOLOGY (2018)
Prevalence of Parkinson's disease across North America
C. Marras et al.
NPJ PARKINSONS DISEASE (2018)
Cannabis Therapeutics and the Future of Neurology
Ethan B. Russo
FRONTIERS IN INTEGRATIVE NEUROSCIENCE (2018)
Cannabidiol reduces ethanol consumption, motivation and relapse in mice
Adrian Viudez-Martinez et al.
ADDICTION BIOLOGY (2018)
Dronabinol increases pain threshold in patients with functional chest pain: a pilot double-blind placebo-controlled trial
Z. Malik et al.
DISEASES OF THE ESOPHAGUS (2017)
Dronabinol Is a Safe Long-Term Treatment Option for Neuropathic Pain Patients
Sebastian Schimrigk et al.
EUROPEAN NEUROLOGY (2017)
Target regulation of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis
Sabrina Giacoppo et al.
FITOTERAPIA (2017)
Endocannabinoid system in neurodegenerative disorders
Balapal S. Basavarajappa et al.
JOURNAL OF NEUROCHEMISTRY (2017)
Inhibition of Reinforcing, Hyperalgesic, and Motor Effects of Morphine by Buspirone in Rats
Darakhshan Jabeen Haleem et al.
JOURNAL OF PAIN (2017)
The endocannabinoid system as a target for novel anxiolytic drugs
Sachin Patel et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2017)
Cannabis constituent synergy in a mouse neuropathic pain model
Sherelle L. Casey et al.
PAIN (2017)
Role of Neuroinflammation in Amyotrophic Lateral Sclerosis: Cellular Mechanisms and Therapeutic implications
Jia Liu et al.
FRONTIERS IN IMMUNOLOGY (2017)
Associations between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study
Jacob M. Vigil et al.
PLOS ONE (2017)
Cannabinoid type 2 receptors in dopamine neurons inhibits psychomotor behaviors, alters anxiety, depression and alcohol preference
Qing-Rong Liu et al.
SCIENTIFIC REPORTS (2017)
Single and combined effects of Δ9-tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain
Kirsten M. King et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies
Marie T. Fallon et al.
BRITISH JOURNAL OF PAIN (2017)
A randomized-controlled trial of nabilone for the prevention of acute postoperative nausea and vomiting in elective surgery
David Neville Levin et al.
CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE (2017)
Effect of food on the pharmacokinetics of dronabinol oral solution versus dronabinol capsules in healthy volunteers
D. Alexander Oh et al.
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS (2017)
Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis
D. C. Hammell et al.
EUROPEAN JOURNAL OF PAIN (2016)
Aberrant epilepsy-associated mutant Nav1.6 sodium channel activity can be targeted with cannabidiol
Reesha R. Patel et al.
BRAIN (2016)
The Effect of Medicinal Cannabis on Pain and Quality-of-Life Outcomes in Chronic Pain: A Prospective Open-label Study
Simon Haroutounian et al.
CLINICAL JOURNAL OF PAIN (2016)
A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease
Jose Luis Lopez-Sendon Moreno et al.
JOURNAL OF NEUROLOGY (2016)
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Orrin Devinsky et al.
LANCET NEUROLOGY (2016)
The effects of Δ9-tetrahydrocannabinol on the dopamine system
Michael A. P. Bloomfield et al.
NATURE (2016)
Serotonin engages an anxiety and fear-promoting circuit in the extended amygdala
Catherine A. Marcinkiewcz et al.
NATURE (2016)
Cannabinoid Type 2 Receptors Mediate a Cell Type-Specific Plasticity in the Hippocampus
A. Vanessa Stempel et al.
NEURON (2016)
Effects of Delta-9-Tetrahydrocannabinol and Cannabidiol on Cisplatin-Induced Neuropathy in Mice
Hannah M. Harris et al.
PLANTA MEDICA (2016)
Medicinal Cannabis: In Vitro Validation of Vaporizers for the Smoke-Free Inhalation of Cannabis
Christian Lanz et al.
PLOS ONE (2016)
Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice
Angelica Pupin Schiavon et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2016)
Conditional anterograde tracing reveals distinct targeting of individual serotonin cell groups (B5-B9) to the forebrain and brainstem
Aude Muzerelle et al.
BRAIN STRUCTURE & FUNCTION (2016)
Stratification of Cannabinoid 1 Receptor (CB1R) Agonist Efficacy: Manipulation of CB1R Density through Use of Transgenic Mice Reveals Congruence between In Vivo and In Vitro Assays
T. W. Grim et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
Bioavailability study of dronabinol oral solution versus dronabinol capsules in healthy volunteers
Neha Parikh et al.
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS (2016)
Serotonin in Parkinson's disease
Marios Polotis et al.
BEHAVIOURAL BRAIN RESEARCH (2015)
The role of serotonin in drug use and addiction
Christian P. Mueller et al.
BEHAVIOURAL BRAIN RESEARCH (2015)
Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS)
Mark A. Ware et al.
JOURNAL OF PAIN (2015)
Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
Theo Vos et al.
LANCET (2015)
Cannabidiol as a Potential Treatment for Anxiety Disorders
Esther M. Blessing et al.
NEUROTHERAPEUTICS (2015)
Further human evidence for striatal dopamine release induced by administration of a†9-tetrahydrocannabinol (THC): selectivity to limbic striatum
Matthijs G. Bossong et al.
PSYCHOPHARMACOLOGY (2015)
Neuroinflammation in Parkinson's disease and its potential as therapeutic target
Qinqin Wang et al.
TRANSLATIONAL NEURODEGENERATION (2015)
Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy
Sara Jane Ward et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
Altered serotonin transporter availability in patients with multiple sclerosis
Swen Hesse et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
THC:CBD Spray and MS Spasticity Symptoms: Data from Latest Studies
Tiina Rekand
EUROPEAN NEUROLOGY (2014)
In vivo type 1 cannabinoid receptor availability in Alzheimer's disease
Rawaha Ahmad et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2014)
Effects of cannabidiol in the treatment of patients with Parkinson's disease: An exploratory double-blind trial
Marcos Hortes N. Chagas et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2014)
Adverse Health Effects of Marijuana Use
Nora D. Volkow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Neuropathic pain in the general population: A systematic review of epidemiological studies
O. van Hecke et al.
PAIN (2014)
Bone cancer pain: from mechanism to therapy
Patrick W. Mantyh
CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE (2014)
A protocol for the delivery of cannabidiol (CBD) and combined CBD and Δ9-tetrahydrocannabinol (THC) by vaporisation
Nadia Solowij et al.
BMC PHARMACOLOGY & TOXICOLOGY (2014)
PTSD Symptom Reports of Patients Evaluated for the New Mexico Medical Cannabis Program
George R. Greer et al.
JOURNAL OF PSYCHOACTIVE DRUGS (2014)
Cannabidiol inhibits the reward-facilitating effect of morphine: involvement of 5-HT1A receptors in the dorsal raphe nucleus
Vicky Katsidoni et al.
ADDICTION BIOLOGY (2013)
Cannabidiol reduces cigarette consumption in tobacco smokers: Preliminary findings
Celia J. A. Morgan et al.
ADDICTIVE BEHAVIORS (2013)
Liposomal drug delivery systems: From concept to clinical applications
Theresa M. Allen et al.
ADVANCED DRUG DELIVERY REVIEWS (2013)
Degeneration of serotonergic neurons in amyotrophic lateral sclerosis: a link to spasticity
Christel Dentel et al.
BRAIN (2013)
Differential expression and functional role of cannabinoid genes in alcohol users
Marisela Agudelo et al.
DRUG AND ALCOHOL DEPENDENCE (2013)
The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system
Alline C. Campos et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2013)
Mesoporous silica-supported lipid bilayers (protocells) for DNA cargo delivery to the spinal cord
Ellen C. Dengler et al.
JOURNAL OF CONTROLLED RELEASE (2013)
CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients
Maite Solas et al.
NEUROBIOLOGY OF AGING (2013)
Targeting 5-HT1A receptors in astrocytes to protect dopaminergic neurons in parkinsonian models
Ikuko Miyazaki et al.
NEUROBIOLOGY OF DISEASE (2013)
Endocannabinoid system and mood disorders: Priming a target for new therapies
Vincenzo Micale et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Involvement of serotonin-mediated neurotransmission in the dorsal periaqueductal gray matter on cannabidiol chronic effects in panic-like responses in rats
Alline Cristina Campos et al.
PSYCHOPHARMACOLOGY (2013)
MUltiple Sclerosis and Extract of Cannabis: results of the MUSEC trial
John Peter Zajicek et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2012)
Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial
Russell K. Portenoy et al.
JOURNAL OF PAIN (2012)
Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: Possible involvement of 5HT1A receptors
Alline Cristina Campos et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2012)
Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo
Koen Van Laere et al.
NEUROBIOLOGY OF AGING (2012)
?9-tetrahydrocannabinol (?9-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease
C. B. Carroll et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2012)
Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats
Yi-Tse Hsiao et al.
NEUROPHARMACOLOGY (2012)
Reduced Forebrain Serotonin Transmission is Causally Involved in the Development of Compulsive Cocaine Seeking in Rats
Yann Pelloux et al.
NEUROPSYCHOPHARMACOLOGY (2012)
Genetics of Parkinson's Disease
Christine Klein et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Cannabidiol Prevents the Development of Cold and Mechanical Allodynia in Paclitaxel-Treated Female C57Bl6 Mice
Sara Jane Ward et al.
ANESTHESIA AND ANALGESIA (2011)
Molecular reorganization of endocannabinoid signalling in Alzheimer's disease
Jan Mulder et al.
BRAIN (2011)
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
Cris S. Constantinescu et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice
Ewa Kozela et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis
A. Novotna et al.
EUROPEAN JOURNAL OF NEUROLOGY (2011)
An Evidence-Based Review of Acute and Long-Term Effects of Cannabis Use on Executive Cognitive Functions
Rebecca D. Crean et al.
JOURNAL OF ADDICTION MEDICINE (2011)
Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice
Maria S. Garcia-Gutierrez et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and In Vivo: Relevance to Alzheimer's Disease
Ana Maria Martin-Moreno et al.
MOLECULAR PHARMACOLOGY (2011)
Brain cannabinoid CB2 receptors modulate cocaine's actions in mice
Zheng-Xiong Xi et al.
NATURE NEUROSCIENCE (2011)
Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naive Social Phobia Patients
Mateus M. Bergamaschi et al.
NEUROPSYCHOPHARMACOLOGY (2011)
Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: Antinociception without central nervous system side-effects
Elizabeth J. Rahn et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2011)
The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors
Felipe V. Gomes et al.
PSYCHOPHARMACOLOGY (2011)
Anatomical study of serotonergic innervation and 5-HT1A receptor in the human spinal cord
F. E. Perrin et al.
CELL DEATH & DISEASE (2011)
CB1 Receptor Blockade Decreases Ethanol Intake and Associated Neurochemical Changes in Fawn-Hooded Rats
Teresa Femenia et al.
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH (2010)
Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors
Vanessa de Paula Soares et al.
BEHAVIOURAL BRAIN RESEARCH (2010)
Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat
Sinead Walsh et al.
BRAIN RESEARCH BULLETIN (2010)
Smoked cannabis for chronic neuropathic pain: a randomized controlled trial
Mark A. Ware et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2010)
Biodegradable polymeric nanoparticles based drug delivery systems
Avnesh Kumari et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2010)
Tau in Alzheimer Disease and Related Tauopathies
K. Iqbal et al.
CURRENT ALZHEIMER RESEARCH (2010)
A behavioural comparison of acute and chronic Δ9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice
Leonora E. Long et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2010)
Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial
M. Weber et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2010)
Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain
Jeremy R. Johnson et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2010)
Cannabidiol Displays Antiepileptiform and Antiseizure Properties In Vitro and In Vivo
Nicholas A. Jones et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis
R. B. C. Kavia et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex
Jasinda H. Lee et al.
NEUROCHEMISTRY INTERNATIONAL (2010)
THE ROLE OF PERIPHERAL 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E AND 5-HT1F SEROTONERGIC RECEPTORS IN THE REDUCTION OF NOCICEPTION IN RATS
V. Granados-Soto et al.
NEUROSCIENCE (2010)
Acute lecozotan administration increases learning and memory in rats without affecting anxiety or behavioral depression
Miguel Skirzewski et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2010)
Disposition of smoked cannabis with high Δ9-tetrahydrocannabinol content: A kinetic model
Claudine C. Hunault et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2010)
22. Cannabinoid and opioid-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling
Jürgen Kraus et al.
BRAIN BEHAVIOR AND IMMUNITY (2009)
Activity of the 5-HT1A receptor is involved in the alteration of glucocorticoid receptor in hippocampus and corticotropin-releasing factor in hypothalamus in SPS rats
Hai-Tao Wang et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2009)
CB1 and CB2 Cannabinoid Receptors Mediate Different Aspects of Delta-9-Tetrahydrocannabinol (THC)-Induced T Helper Cell Shift Following Immune Activation by Legionella Pneumophila Infection
Catherine A. Newton et al.
JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2009)
Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship
Peter T. Nelson et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2009)
Cannabidiol, a Nonpsychotropic Component of Cannabis, Inhibits Cue-Induced Heroin Seeking and Normalizes Discrete Mesolimbic Neuronal Disturbances
Yanhua Ren et al.
JOURNAL OF NEUROSCIENCE (2009)
Cannabidiol for the treatment of psychosis in Parkinson's disease
A. W. Zuardi et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2009)
A Pilot Study Using Nabilone for Symptomatic Treatment in Huntington's Disease
Adrienne Curtis et al.
MOVEMENT DISORDERS (2009)
ALTERED CB1 RECEPTOR AND ENDOCANNABINOID LEVELS PRECEDE MOTOR SYMPTOM ONSET IN A TRANSGENIC MOUSE MODEL OF HUNTINGTON'S DISEASE
M. J. Dowie et al.
NEUROSCIENCE (2009)
Cannabinoid CB1 Receptors are Early DownRegulated Followed by a Further UpRegulation in the Basal Ganglia of Mice with Deletion of Specific Park Genes
Moises Garcia-Arencibia et al.
JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT (2009)
Behavioral Effects of CB2 Cannabinoid Receptor Activation and Its Influence on Food and Alcohol Consumption
E. S. Onaivi et al.
DRUG ADDICTION: RESEARCH FRONTIERS AND TREATMENT ADVANCES (2008)
Functional Expression of Brain Neuronal CB2 Cannabinoid Receptors Are Involved in the Effects of Drugs of Abuse and in Depression
Emmanuel S. Onaivi et al.
DRUG ADDICTION: RESEARCH FRONTIERS AND TREATMENT ADVANCES (2008)
The role of 5-HT1A receptors in learning and memory
Sven Ove Ogren et al.
BEHAVIOURAL BRAIN RESEARCH (2008)
A review of Parkinson's disease
C. A. Davie
BRITISH MEDICAL BULLETIN (2008)
Analgesic and antihyperalgesic effects of nabilone on experimental heat pain
William John Redmond et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity
Pingwei Zhao et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2008)
Therapeutic effects of Δ9-THC and modafinil in a marmoset Parkinson model
Sanneke A. M. van Vliet et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2008)
The CB2 cannabinoid receptor controls myeloid progenitor trafficking
Javier Palazuelos et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Crucial Role of CB2 Cannabinoid Receptor in the Regulation of Central Immune Responses during Neuropathic Pain
Ildiko Racz et al.
JOURNAL OF NEUROSCIENCE (2008)
Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats
Alline Cristina Campos et al.
PSYCHOPHARMACOLOGY (2008)
Preferential loss of serotonin markers in caudate versus putamen in Parkinsons disease
Stephen J. Kish et al.
BRAIN (2008)
Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial
Turo J. Nurmikko et al.
PAIN (2007)
The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear extinction
Pauline Lafentre et al.
PHARMACOLOGICAL RESEARCH (2007)
Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors
Onintza Sagredo et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2007)
The partial 5-HT1A agonist buspirone reduces the expression and development of I-DOPA-induced dyskinesia in rats and improves I-DOPA efficacy
Karen L. Eskow et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2007)
A preliminary open-label study of 5-HT1A partial agonist tandospirone for behavioural and psychological symptoms associated with dementia
Shinji Sato et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2007)
Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis
C. Collin et al.
EUROPEAN JOURNAL OF NEUROLOGY (2007)
Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats
Maria Ellgren et al.
NEUROPSYCHOPHARMACOLOGY (2007)
Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis
Cristina Benito et al.
JOURNAL OF NEUROSCIENCE (2007)
The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain
Barbara Costa et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
Cannabinoid CB2 receptor: a new target for controlling neural cell survival?
Javier Fernandez-Ruiz et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2007)
Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis
D. T. Wade et al.
MULTIPLE SCLEROSIS JOURNAL (2006)
Interactions between CB1 cannabinoid and μ opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core
A. N. M. Schoffelmeer et al.
NEUROPHARMACOLOGY (2006)
Serotonergic mechanisms in amyotrophic lateral sclerosis
Reuven Sandyk
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2006)
Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice
Lynsey G. Bilsland et al.
FASEB JOURNAL (2006)
COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord
Y Yiangou et al.
BMC NEUROLOGY (2006)
CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms
M Beltramo et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2006)
Ethanol self-administration and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB1 receptors
PK Thanos et al.
BEHAVIOURAL BRAIN RESEARCH (2005)
Identification and functional characterization of brainstem cannabinoid CB2 receptors
MD Van Sickle et al.
SCIENCE (2005)
Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli
K Maresz et al.
JOURNAL OF NEUROCHEMISTRY (2005)
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
DJ Rog et al.
NEUROLOGY (2005)
Lecozotan (SRA-333): A selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties
LE Schechter et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Role of transient receptor potential vanilloid 1 receptors in adjuvant-induced chronic arthritis:: In vivo study using gene-deficient mice
A Szabó et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro:: Relevance to Parkinson's disease
I Lastres-Becker et al.
NEUROBIOLOGY OF DISEASE (2005)
Dopamine and serotonin release in dorsal striatum and nucleus accumbens is differentially modulated by morphine in DBA/2J and C57BL/6J mice
P Fadda et al.
SYNAPSE (2005)
Prevention of Alzheimer's disease pathology by cannabinoids:: Neuroprotection mediated by blockade of microglial activation
BG Ramírez et al.
JOURNAL OF NEUROSCIENCE (2005)
Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival
P Weydt et al.
AMYOTROPHIC LATERAL SCLEROSIS (2005)
Delta(9)-THC reinstates beer- and sucrose-seeking behaviour in abstinent rats: Comparison with midazolam, food deprivation and predator odour
IS McGregor et al.
ALCOHOL AND ALCOHOLISM (2005)
Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons
G Wotherspoon et al.
NEUROSCIENCE (2005)
Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: Reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716)
C Cohen et al.
NEUROPSYCHOPHARMACOLOGY (2005)
Are oral cannabinoids safe and effective in refractory neuropathic pain?
N Attal et al.
EUROPEAN JOURNAL OF PAIN (2004)
Combined low dose treatment with opioid and cannabinoid receptor antagonists synergistically reduces the motivation to consume alcohol in rats
JE Gallate et al.
PSYCHOPHARMACOLOGY (2004)
Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid
C Raman et al.
AMYOTROPHIC LATERAL SCLEROSIS (2004)
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial
KB Svendsen et al.
BMJ-BRITISH MEDICAL JOURNAL (2004)
Exposure to Δ-9-tetrahydrocannabinol (THC) increases subsequent heroin taking but not heroin's reinforcing efficacy:: A self-administration study in rats
M Solinas et al.
NEUROPSYCHOPHARMACOLOGY (2004)
Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice
EA McCaw et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2004)
Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients
DT Wade et al.
MULTIPLE SCLEROSIS (2004)
Δ9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice
GN Balerio et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2004)
Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo
I Lastres-Becker et al.
NEUROREPORT (2004)
Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 'N of 1' studies
W Notcutt et al.
ANAESTHESIA (2004)
Cannabidiol - transdermal delivery and anti-inflammatory effect in a murine model
M Lodzki et al.
JOURNAL OF CONTROLLED RELEASE (2003)
CB1 cannabinoid receptors and on-demand defense against excitotoxicity
G Marsicano et al.
SCIENCE (2003)
The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy
MJ Wallace et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis
G Pryce et al.
BRAIN (2003)
Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats
TJ De Vries et al.
PSYCHOPHARMACOLOGY (2003)
Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease
MKP Lai et al.
BRAIN RESEARCH (2003)
Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models
J Zhang et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2003)
Profound, non-opioid analgesia produced by the high-efficacy 5-HT1A agonist F 13640 in the formalin model of tonic nociceptive pain
L Bardin et al.
PHARMACOLOGY (2003)
Apoptosis in Huntington's disease
MA Hickey et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2003)
Tremor in Parkinson's disease and serotonergic dysfunction -: An 11C-WAY 100635 PET study
M Doder et al.
NEUROLOGY (2003)
The neuronal distribution of cannabinoid receptor type 1 in the trigeminal ganglion of the rat
TJ Price et al.
NEUROSCIENCE (2003)
Pharmacokinetics and pharmacodynamics of cannabinoids
F Grotenhermen
CLINICAL PHARMACOKINETICS (2003)
Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain
MJ Hurley et al.
JOURNAL OF NEURAL TRANSMISSION (2003)
Inhibition of tryptophan hydroxylase activity and decreased 5-HT1A receptor binding in a mouse model of Huntington's disease
GJ Yohrling et al.
JOURNAL OF NEUROCHEMISTRY (2002)
Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease
I Lastres-Becker et al.
SYNAPSE (2002)
Ethanol-stimulated serotonin release in the ventral hippocampus: an absence of rapid tolerance for the alcohol-preferring P rat and insensitivity in the alcohol-nonpreferring NP rat
RJ Thielen et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2002)
Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine
E Valjent et al.
BRITISH JOURNAL OF PHARMACOLOGY (2002)
Autoradiographic study of pre- and postnatal distribution of cannabinoid receptors in human brain
A Biegon et al.
NEUROIMAGE (2001)
Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission
I Katona et al.
JOURNAL OF NEUROSCIENCE (2001)
Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain
SM Huang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Changes in cannabinoid CB1 receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis
F Berrendero et al.
SYNAPSE (2001)
Cannabinoid actions on rat superficial medullary dorsal horn neurons in vitro
EA Jennings et al.
JOURNAL OF PHYSIOLOGY-LONDON (2001)
Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease
I Lastres-Becker et al.
NEUROREPORT (2001)
Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease
MA Silverdale et al.
EXPERIMENTAL NEUROLOGY (2001)
Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals
T Ohno-Shosaku et al.
NEURON (2001)
Ultrastructural localization of the CB1 cannabinoid receptor in μ-opioid receptor patches of the rat caudate putamen nucleus
JJ Rodríguez et al.
JOURNAL OF NEUROSCIENCE (2001)
Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice
EM Denovan-Wright et al.
NEUROSCIENCE (2000)
分享论文
